FinancialContent is the trusted provider of stock market information to the media industry
Idenix Reports Upbeat Interim Results
Posted on June 20, 2012 at 18:50 PM EDT
Idenix Pharmaceuticals Inc. (Nasdaq: IDIX) reported upbeat interim results from a Phase IIb clinical trial of its HCV inhibitor drugs IDX184 and IDX719 sending the stock price soaring $1.34 to close at $10.71.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here